The cancer-specific susceptibility to BET inhibition has been explained by the acquisition of super-enhancers during tumorigenesis and a preferential loss of BRD4 from the mediator complex at super-enhancers upon treatment with BET inhibitors [43,75]. This evidence concerns the gene BRD4 and cancer.